大肠杆菌
基因工程
疾病
医学
生物
生物信息学
免疫学
癌症研究
遗传学
基因
病理
作者
Jason P. Lynch,Lisa Goers,Cammie F. Lesser
标识
DOI:10.1016/j.tips.2022.02.002
摘要
Engineered microbes are rapidly being developed for the delivery of therapeutic modalities to sites of disease. Escherichia coli Nissle 1917 (EcN), a genetically tractable probiotic with a well-established human safety record, is emerging as a favored chassis. Here, we summarize the latest progress in rationally engineered variants of EcN for the treatment of infectious diseases, metabolic disorders, and inflammatory bowel diseases (IBDs) when administered orally, as well as cancers when injected directly into tumors or the systemic circulation. We also discuss emerging studies that raise potential safety concerns regarding these EcN-based strains as therapeutics due to their secretion of a genotoxic colibactin that can promote the formation of DNA double-stranded breaks in mammalian DNA.
科研通智能强力驱动
Strongly Powered by AbleSci AI